LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: Implication for mitochondrial dysfunction in Parkinson's disease

Abstract Exposure to rotenone in vivo results in selective degeneration of dopaminergic neurons and development of neuropathologic features of Parkinson's disease (PD). As rotenone acts as an inhibitor of mitochondrial respiratory complex I, we employed oxidative lipidomics to assess oxidative metabolism of a mitochondria-specific phospholipid, cardiolipin (CL), in substantia nigra (SN) of exposed animals. We found a significant reduction in oxidizable polyunsaturated fatty acid (PUFA)-containing CL molecular species. We further revealed increased contents of mono-oxygenated CL species at late stages of the exposure. Notably, linoleic acid in sn-1 position was the major oxidation substrate yielding its mono-hydroxy- and epoxy-derivatives whereas more readily “oxidizable” fatty acid residues (arachidonic and docosahexaenoic acids) remained non-oxidized. Elevated levels of PUFA CLs were detected in plasma of rats exposed to rotenone. Characterization of oxidatively modified CL molecular species in SN and detection of PUFA-containing CL species in plasma may contribute to better understanding of the PD pathogenesis and lead to the development of new biomarkers of mitochondrial dysfunction associated with this disease.

[1]  E. H. Howlett,et al.  Mitochondrial DNA damage as a peripheral biomarker for mitochondrial toxin exposure in rats. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  C. Chu,et al.  Mitochondrial DNA damage: Molecular marker of vulnerable nigral neurons in Parkinson's disease , 2014, Neurobiology of Disease.

[3]  B. Fadeel,et al.  Mitochondria released by cells undergoing TNF-α-induced necroptosis act as danger signals , 2014, Cell Death and Disease.

[4]  D. Pfeiffer,et al.  Regulation of the Ca2-independent phospholipase A2 in liver mitochondria by changes in the energetic state , 2014, Journal of Lipid Research.

[5]  J. Klein-Seetharaman,et al.  mitochondrial pathway for biosynthesis of lipid mediators , 2014, Nature chemistry.

[6]  H. Bayır,et al.  Cardiolipin asymmetry, oxidation and signaling. , 2014, Chemistry and physics of lipids.

[7]  G. Paradies,et al.  Functional role of cardiolipin in mitochondrial bioenergetics. , 2014, Biochimica et biophysica acta.

[8]  H. Bayır,et al.  Characterization of cardiolipins and their oxidation products by LC-MS analysis. , 2014, Chemistry and physics of lipids.

[9]  I. Celardo,et al.  Unravelling mitochondrial pathways to Parkinson's disease , 2014, British journal of pharmacology.

[10]  A. Federico,et al.  Apoptosis and oxidative stress in neurodegenerative diseases. , 2014, Journal of Alzheimer's disease : JAD.

[11]  Simon C Watkins,et al.  Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells , 2013, Nature Cell Biology.

[12]  L. Sanders,et al.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. , 2013, Free radical biology & medicine.

[13]  Y. Tyurina,et al.  LC/MS characterization of rotenone induced cardiolipin oxidation in human lymphocytes: implications for mitochondrial dysfunction associated with Parkinson's disease. , 2013, Molecular nutrition & food research.

[14]  P. Ježek,et al.  Antioxidant activity by a synergy of redox-sensitive mitochondrial phospholipase A2 and uncoupling protein-2 in lung and spleen. , 2013, The international journal of biochemistry & cell biology.

[15]  V. O’Donnell,et al.  Oxidized PLs and Vascular Inflammation , 2013, Current Atherosclerosis Reports.

[16]  J. Li,et al.  Oxidative Stress and Neurodegenerative Disorders , 2007, International journal of molecular sciences.

[17]  E. Junn,et al.  The role of oxidative stress in Parkinson's disease. , 2013, Journal of Parkinson's disease.

[18]  Nektarios Tavernarakis,et al.  Mitophagy in neurodegeneration and aging , 2012, Front. Gene..

[19]  P. Kochanek,et al.  Global lipidomics identifies cardiolipin oxidation as a mitochondrial target for redox therapy of acute brain injury , 2012, Nature Neuroscience.

[20]  Terina N. Martinez,et al.  Toxin models of mitochondrial dysfunction in Parkinson's disease. , 2012, Antioxidants & redox signaling.

[21]  H. Bayır,et al.  Oxidized phospholipids as biomarkers of tissue and cell damage with a focus on cardiolipin. , 2012, Biochimica et biophysica acta.

[22]  Rou-shayn Chen,et al.  PLA2G6 mutations in PARK14‐linked young‐onset parkinsonism and sporadic Parkinson's disease , 2012, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[23]  Riitta Lahesmaa,et al.  Global phospholipidomics analysis reveals selective pulmonary peroxidation profiles upon inhalation of single-walled carbon nanotubes. , 2011, ACS nano.

[24]  W. Oertel,et al.  The PLA2G6 gene in early‐onset Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[25]  B. Lambrecht,et al.  Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. , 2011, Trends in immunology.

[26]  J. Greenberger,et al.  Oxidative Lipidomics of γ-Radiation-Induced Lung Injury: Mass Spectrometric Characterization of Cardiolipin and Phosphatidylserine Peroxidation , 2011, Radiation research.

[27]  D. Prou,et al.  Toxin-induced models of Parkinson’s disease , 2005, NeuroRX.

[28]  M. Valko,et al.  Metals, oxidative stress and neurodegenerative disorders , 2010, Molecular and Cellular Biochemistry.

[29]  Simon Watkins,et al.  Oxidative lipidomics of hyperoxic acute lung injury: mass spectrometric characterization of cardiolipin and phosphatidylserine peroxidation. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[30]  V. Bochkov,et al.  Generation and biological activities of oxidized phospholipids. , 2010, Antioxidants & redox signaling.

[31]  P. Mastroberardino,et al.  Lessons from the rotenone model of Parkinson's disease. , 2010, Trends in pharmacological sciences.

[32]  M. Schlame,et al.  The role of cardiolipin in the structural organization of mitochondrial membranes. , 2009, Biochimica et biophysica acta.

[33]  N. Wood,et al.  Cell death pathways in Parkinson's disease: role of mitochondria. , 2009, Antioxidants & redox signaling.

[34]  E. Podrez,et al.  Oxidized phospholipids: biomarker for cardiovascular diseases. , 2009, The international journal of biochemistry & cell biology.

[35]  Michael P. Murphy,et al.  How mitochondria produce reactive oxygen species , 2008, The Biochemical journal.

[36]  Xianlin Han,et al.  Examination of the brain mitochondrial lipidome using shotgun lipidomics. , 2009, Methods in molecular biology.

[37]  M. Beal,et al.  Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis , 2008, Nature Clinical Practice Neurology.

[38]  J. Greenberger,et al.  Oxidative lipidomics of gamma-irradiation-induced intestinal injury. , 2008, Free radical biology & medicine.

[39]  M. Bogdanov,et al.  Lipids in the assembly of membrane proteins and organization of protein supercomplexes: implications for lipid-linked disorders. , 2008, Sub-cellular biochemistry.

[40]  Rosa Viner,et al.  Selective early cardiolipin peroxidation after traumatic brain injury: an oxidative lipidomics analysis , 2007, Annals of neurology.

[41]  Colin A. Johnson,et al.  Corrigendum: PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron , 2006, Nature Genetics.

[42]  Colin A. Johnson,et al.  PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron , 2006, Nature Genetics.

[43]  M. Sharpley,et al.  Interactions between phospholipids and NADH:ubiquinone oxidoreductase (complex I) from bovine mitochondria. , 2006, Biochemistry.

[44]  S. Fleischer,et al.  Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots , 1970, Lipids.

[45]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[46]  Todd Sherer,et al.  Rotenone Model of Parkinson Disease , 2005, Journal of Biological Chemistry.

[47]  Qing Zhao,et al.  Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors , 2005, Nature chemical biology.

[48]  R. Murphy,et al.  Quantitation of cardiolipin molecular species in spontaneously hypertensive heart failure rats using electrospray ionization mass spectrometry Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M500031-JLR200 , 2005, Journal of Lipid Research.

[49]  T. Sherer,et al.  Oxidative damage in Parkinson's disease. , 2005, Antioxidants & redox signaling.

[50]  Claudia M Testa,et al.  Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. , 2005, Brain research. Molecular brain research.

[51]  A. Brash,et al.  A single active site residue directs oxygenation stereospecificity in lipoxygenases: stereocontrol is linked to the position of oxygenation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  T. Sherer,et al.  Animal models of Parkinson's disease. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[53]  T. Sherer,et al.  Complex I and Parkinson's Disease , 2001, IUBMB life.

[54]  T. Shike,et al.  Animal models. , 2001, Contributions to nephrology.

[55]  M. Beal Oxidative Damage in Parkinson's Disease , 2000 .

[56]  A. Sun,et al.  Oxidative Stress and Neurodegenerative Disorders , 1998, Journal of Biomedical Science.

[57]  M. Bard,et al.  Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae , 1998, Yeast.

[58]  D. Perl,et al.  Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.

[59]  C D Marsden,et al.  Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.

[60]  P. Riederer,et al.  The soluble form of Fas molecule is elevated in parkinsonian brain tissues , 1996, Neuroscience Letters.

[61]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  N. C. Robinson,et al.  Functional binding of cardiolipin to cytochromec oxidase , 1993, Journal of bioenergetics and biomembranes.

[63]  K. Jellinger,et al.  Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.

[64]  W. Coleman,et al.  Tightly associated cardiolipin in the bovine heart mitochondrial ATP synthase as analyzed by 31P nuclear magnetic resonance spectroscopy. , 1990, The Journal of biological chemistry.

[65]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[66]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[67]  V. Kagan Lipid Peroxidation In Biomembranes , 1988 .

[68]  D. E. Green,et al.  Cardiolipin requirement for electron transfer in complex I and III of the mitochondrial respiratory chain. , 1981, The Journal of biological chemistry.

[69]  C. Böttcher,et al.  A rapid and sensitive sub-micro phosphorus determination , 1961 .

[70]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[71]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.